TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $225
AbbVie Is Maintained at Buy by TD Cowen
AbbVie Analyst Ratings
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $212
AbbVie (ABBV) Gets a Buy From Barclays
Barclays Adjusts Price Target on AbbVie to $212 From $200, Maintains Overweight Rating
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $218
Redburn Atlantic Adjusts Price Target on AbbVie to $215 From $203, Maintains Buy Rating
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $214
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $209
DBS Initiates AbbVie(ABBV.US) With Hold Rating
Maintaining a Hold: Balancing AbbVie's Strategic Successes Against Market Challenges
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $218
Positive Outlook for AbbVie: Buy Rating Affirmed Amid Strong Aesthetics Sales and Market Share Stability
Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating
AbbVie Price Target Raised to $209.00/Share From $196.00 by Piper Sandler
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $209